开始低剂量纳曲酮（LDN）后甲状腺激素的消耗没有变化：一项准实验前后研究。
No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study.
机构信息
Regional Medicines Information and Pharmacovigilance Centre (RELIS), University Hospital of North Norway, Tromsø, Norway.
Raknes Research, Ulset, Norway.
出版信息
BMC Endocr Disord. 2020 Oct 1;20(1):151. doi: 10.1186/s12902-020-00630-4.
BACKGROUND
Low dose naltrexone (LDN) is reported to have beneficial effects in several autoimmune diseases. The purpose of this study was to examine whether starting LDN was followed by changes in the dispensing of thyroid hormones to patients with hypothyroidism.
METHODS
We performed a quasi-experimental before-after study based on the Norwegian Prescription Database. Study participants were identified by using reimbursement codes for hypothyroidism. Cumulative dispensed Defined Daily Doses and the number of users of triiodothyronine (T3) and levothyroxine (LT4) 1 year before and after the first LDN prescription was compared in three groups based on LDN exposure.
RESULTS
We identified 898 patients that met the inclusion criteria. There was no association between starting LDN and the subsequent dispensing of thyroid hormones. If anything, there was a tendency towards increasing LT4 consumption with increasing LDN exposure.
CONCLUSION
The results of this study do not support claims of efficacy of LDN in hypothyroidism.
背景
低剂量纳曲酮（LDN）据报道对几种自身免疫性疾病有有益的作用。本研究的目的是检验开始使用 LDN 是否会导致甲状腺功能减退症患者的甲状腺激素配给发生变化。
方法
我们基于挪威处方数据库进行了一项准实验前后研究。通过使用甲状腺功能减退症的报销代码来识别研究参与者。在 LDN 处方开出后的 1 年内，根据 LDN 的暴露情况，将三种组别患者的累积配给的限定日剂量和三碘甲状腺原氨酸（T3）和左甲状腺素（LT4）的使用者数量进行了比较。
结果
我们确定了 898 名符合纳入标准的患者。开始使用 LDN 与随后的甲状腺激素配给之间没有关联。如果有的话，随着 LDN 暴露的增加，LT4 的使用量也有增加的趋势。
结论
本研究结果不支持 LDN 在甲状腺功能减退症中的疗效的说法。
Zotero 插件